Associated Papers
Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia.
Hristodor AM et al.
Cell Death Discovery, 2025
40544182 (PubMed )
Supplement: 41420_2025_2571_MOESM1_ESM.pdf
Pathogenic variants in human DNA damage repair genes mostly arose in recent human history.
Zhao B et al.
Bmc Cancer, 2024
38575974 (PubMed )
Supplement: 12885_2024_12160_MOESM6_ESM.xlsx › Sheet1
Pathogenic variants in human DNA damage repair genes mostly arose after the latest human out-of-Africa migration.
He J et al.
Frontiers in Genetics, 2024
38948361 (PubMed )
Supplement: Table6.XLSX › Sheet1
Differential Regulation of Retinoic Acid Metabolism in Fanconi Anemia.
Blaize JL et al.
Biorxiv : the Preprint Server for Biology, 2023
The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
Tone AA et al.
Gynecologic Oncology, 2021
Prediction of breast cancer risk based on flow-variant analysis of circulating peripheral blood B cells.
Syeda MM et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes.
Levitus M et al.
Blood, 2004
The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG.
de Winter JP et al.
Human Molecular Genetics, 2000
Select a paper to view details